Overview

Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants

Status:
Not yet recruiting

Trial end date:
2023-05-03

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to determine whether aspirin alone or aspirin combined with various doses of rivaroxaban causes subclinical GI blood loss as determined by the HemoQuant assay. The secondary objective of the study is to evaluate the safety and tolerability of aspirin alone or in combination with rivaroxaban to healthy volunteers.

Phase:

N/A

Details

Lead Sponsor:

Regeneron Pharmaceuticals

Treatments:

Aspirin
Rivaroxaban